Ocular Therapeutix

OCUL · NASDAQ

$6.65+$0.36 (+5.72%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.29

Latest news

Press releaseSep 15, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
NewsAug 17, 1:48 PM ETVandana Singh
Why Is Ocular Therapeutix Stock Gaining Monday?
NewsAug 17, 9:51 AM ETAvi Kapoor
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
NewsAug 17, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseAug 3, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
NewsJun 17, 10:55 AM ETVandana Singh
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Press releaseJun 17, 8:45 AM ETGlobe Newswire
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Press releaseJun 2, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
NewsMay 11, 8:02 AM ETAvi Kapoor
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseMay 5, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Press releaseApr 29, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
NewsApr 13, 1:31 PM ETVandana Singh
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
Press releaseApr 13, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
NewsFeb 18, 8:01 AM ET
Ocular Therapeutix Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
NewsFeb 17, 12:14 PM ETAvi Kapoor
Gold Down 3%; Medtronic Earnings Top Views
NewsFeb 17, 9:15 AM ETVandana Singh
Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes
NewsFeb 17, 8:38 AM ETRishabh Mishra
Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)
NewsFeb 17, 7:35 AM ET
Market-Moving News for February 17th
Press releaseFeb 17, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
Press releaseFeb 5, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
NewsJan 15, 10:30 AM ETDylan Berman
Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
NewsAug 4, 4:04 PM ET
What's Next: Ocular Therapeutix's Earnings Preview
NewsMay 29, 3:02 PM ET
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
NewsMay 20, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
NewsMay 6, 8:01 AM ET
Analyst Expectations For Ocular Therapeutix's Future
NewsMay 5, 4:07 PM ETHenry Khederian
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
NewsApr 8, 10:01 AM ET
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts
NewsApr 8, 8:53 AM ETAvi Kapoor
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
NewsMar 18, 6:01 PM ET
What 4 Analyst Ratings Have To Say About Ocular Therapeutix
NewsDec 3, 12:00 PM ET
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
NewsNov 13, 10:01 AM ET
A Peek at Ocular Therapeutix's Future Earnings
Press releaseAug 7, 7:00 AM ETGlobe Newswire
Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
NewsAug 1, 2:05 PM ET
Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Why Is Ocular Therapeutix Stock Gaining Monday?

H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday

12 Health Care Stocks Moving In Monday's Pre-Market Session

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Earnings Scheduled For May 5, 2026

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Gold Down 3%; Medtronic Earnings Top Views

Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes

Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)

Market-Moving News for February 17th

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid

Earnings Scheduled For August 5, 2025

What's Next: Ocular Therapeutix's Earnings Preview

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews

10 Health Care Stocks With Whale Alerts In Today's Session

Analyst Expectations For Ocular Therapeutix's Future

Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings

Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts

This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

What 4 Analyst Ratings Have To Say About Ocular Therapeutix

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts

A Peek at Ocular Therapeutix's Future Earnings

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock